Sun Pharmaceutical Stock Screener | Share Price & Fundamental Analysis
SUNPHARMA
Pharmaceuticals
Screen Sun Pharmaceutical share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1728.90
▲
0.90 (0.05%)
Share Price BSE
₹1730.15
▲
0.80 (0.05%)
Market Cap
₹412,613.60 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
5.30
EPS (TTM)
₹45.60
Dividend Yield
0.93%
Debt to Equity
0.04
52W High
₹1853.40
52W Low
₹1562.80
Operating Margin
31.00%
Profit Margin
21.01%
Revenue (TTM)
₹14,875.00
EBITDA
₹4,924.00
Net Income
₹3,125.00
Total Assets
₹92,101.00
Total Equity
₹72,486.00
Sun Pharmaceutical Share Price History - Stock Screener Chart
Screen SUNPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Sun Pharmaceutical Company Profile - Fundamental Screener
Screen Sun Pharmaceutical company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUNPHARMA shares.
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Dilip S Shanghvi
ISIN
INE044A01036
Website
https://www.sunpharma.com
Sun Pharmaceutical Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen SUNPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 92,101 | 85,500 | 80,744 | 69,808 | 67,667 | 68,253 | 64,694 | 64,516 | 61,410 | 55,530 |
| Current Assets | 52,594 | 43,433 | 39,862 | 34,865 | 30,442 | 31,654 | 31,069 | 31,636 | 32,954 | 29,941 |
| Fixed Assets | 22,586 | 23,248 | 24,065 | 22,665 | 21,553 | 22,847 | 21,837 | 18,853 | 17,675 | 15,872 |
| Liabilities | ||||||||||
| Total Liabilities | 92,101 | 85,500 | 80,744 | 69,808 | 67,667 | 68,253 | 64,694 | 64,516 | 61,410 | 55,530 |
| Current Liabilities | 1,420 | 1,390 | 1,522 | 1,533 | 2,041 | 3,421 | 2,632 | 2,454 | 3,093 | 5,319 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 72,486 | 67,126 | 59,316 | 51,066 | 49,480 | 49,125 | 44,723 | 42,198 | 40,431 | 37,068 |
| Share Capital | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 241 |
| Reserves & Surplus | 71,978 | 63,427 | 55,755 | 47,771 | 46,223 | 45,025 | 41,169 | 38,074 | 36,400 | 32,741 |
Screen SUNPHARMA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14,875 | 14,251 | 13,429 | 13,903 | 13,618 | 13,057 | 12,419 | 12,407 | 12,297 | 11,990 | 11,099 | 11,274 | 10,894 | 10,646 | 9,500 |
| Expenses | 9,951 | 10,368 | 9,604 | 9,983 | 9,352 | 9,045 | 9,049 | 8,974 | 9,013 | 8,932 | 8,300 | 8,237 | 7,996 | 7,877 | 11,042 |
| EBITDA | 4,924 | 3,883 | 3,824 | 3,920 | 4,266 | 4,012 | 3,370 | 3,433 | 3,284 | 3,058 | 2,799 | 3,037 | 2,899 | 2,769 | -1,542 |
| Operating Profit % | 31.00% | 25.00% | 25.00% | 26.00% | 29.00% | 28.00% | 23.00% | 26.00% | 25.00% | 24.00% | 23.00% | 26.00% | 26.00% | 26.00% | -18.00% |
| Depreciation | 730 | 701 | 664 | 631 | 626 | 655 | 650 | 622 | 633 | 651 | 672 | 660 | 610 | 588 | 557 |
| Interest | 100 | 75 | 49 | 52 | 69 | 62 | 74 | 35 | 49 | 81 | 93 | 46 | 19 | 14 | 37 |
| Profit Before Tax | 4,168 | 3,173 | 3,254 | 3,476 | 3,598 | 3,424 | 2,816 | 3,000 | 2,791 | 2,481 | 2,240 | 2,472 | 2,412 | 2,285 | -2,076 |
| Tax | 1,043 | 880 | 1,100 | 563 | 561 | 563 | 157 | 440 | 406 | 476 | 257 | 291 | 157 | 191 | 152 |
| Net Profit | 3,125 | 2,293 | 2,154 | 2,913 | 3,037 | 2,861 | 2,659 | 2,561 | 2,385 | 2,006 | 1,983 | 2,181 | 2,256 | 2,093 | -2,227 |
| EPS | 13.00 | 9.50 | 9.00 | 12.10 | 12.70 | 11.80 | 11.10 | 10.50 | 9.90 | 8.40 | 8.30 | 9.00 | 9.40 | 8.60 | -9.50 |
Sun Pharmaceutical Cash Flow Screener - Liquidity Fundamentals
Screen SUNPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 14,072 | 12,135 | 4,959 | 8,985 | 6,170 | 6,555 | 2,196 | 3,907 | 7,082 | 6,686 |
| Investing Activities | -5,183 | -763 | -7,220 | -5,556 | 407 | -2,225 | -310 | -3,104 | -4,186 | -3,949 |
| Financing Activities | -7,906 | -6,710 | 2,376 | -5,194 | -5,981 | -5,715 | -2,731 | -1,539 | -2,285 | -1,889 |
| Net Cash Flow | 983 | 4,662 | 116 | -1,765 | 596 | -1,386 | -844 | -736 | 611 | 848 |
Screen SUNPHARMA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
| FII Holding | 16.55% | 17.26% | 17.96% | 18.05% | 18.02% | 17.23% | 17.72% | 0.00% |
| DII Holding | 20.24% | 19.50% | 18.70% | 18.55% | 18.61% | 19.28% | 18.83% | 17.97% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.53% | 5.35% | 5.42% | 5.47% | 5.43% | 5.57% | 5.44% | 5.41% |
| Other Holding | 3.20% | 3.42% | 3.45% | 3.46% | 3.46% | 3.44% | 3.53% | 22.13% |
| Shareholder Count | 743,877 | 723,770 | 704,983 | 689,623 | 657,317 | 673,217 | 631,392 | 612,626 |
Sun Pharmaceutical Dividend Screener - Share Yield Analysis
Screen SUNPHARMA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹16.00 | 0.93% |
| 2024-March | ₹13.50 | 0.78% |
| 2023-March | ₹11.50 | 0.71% |
| 2022-March | ₹10.00 | 1.01% |
| 2021-March | ₹7.50 | 0.82% |
| 2020-March | ₹4.00 | 0.67% |
| 2019-March | ₹2.75 | 0.78% |
| 2018-March | ₹2.00 | 0.42% |
| 2017-March | ₹3.50 | 0.71% |
Sun Pharmaceutical Index Membership - Market Screener Classification
Screen SUNPHARMA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Sun Pharmaceutical Market Events Screener - Corporate Actions
Screen SUNPHARMA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | 1.29% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 0.19% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | 4.32% |
| 2025-07-07 | 2025-07-07 | Dividend | ₹ 5.50 /share | -3.17% |
| 2025-05-22 | 2025-05-22 | Quarterly Result Announcement | NA | -0.76% |
| 2025-02-06 | 2025-02-06 | Dividend | ₹ 10.50 /share | 0.82% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -1.01% |
| 2025-01-21 | 2025-01-21 | Extraordinary General Meeting | NA | -1.55% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -2.94% |
| 2024-08-05 | 2024-08-05 | Annual General Meeting | NA | 13.88% |
| 2024-07-12 | 2024-07-12 | Dividend | ₹ 5.00 /share | 2.73% |
| 2024-02-09 | 2024-02-09 | Dividend | ₹ 8.50 /share | 9.38% |
| 2023-07-28 | 2023-07-28 | Dividend | ₹ 4.00 /share | 20.10% |
| 2023-02-08 | 2023-02-08 | Dividend | ₹ 7.50 /share | -4.31% |
| 2022-08-19 | 2022-08-22 | Dividend | ₹ 3.00 /share | -0.28% |
Sun Pharmaceutical Competitors Screener - Peer Comparison
Screen SUNPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,614 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 169,701 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 130,302 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 122,079 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 106,115 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 96,362 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 92,005 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 90,673 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 68,709 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,839 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Sun Pharmaceutical Company Announcements - News Screener
Screen SUNPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-04 | Closure of Trading Window | View |
| 2026-01-01 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-12-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-18 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - US FDA Determines Baska Facility Inspection Classification As OAI | View |
| 2025-12-02 | Intimation Under Regulation 30 - Approval Of Proposal For Greenfield Project | View |
| 2025-12-01 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-22 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-05 | Investor Call Audio Recording | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | View |
| 2025-11-05 | Financial Results For The Quarter And Half-Year Ended 30 September 2025 | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |